The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Travel Stocks Suffer As UK Extends Quarantine

Fri, 14th Aug 2020 12:12

(Alliance News) - Stocks in London were shaky at midday on Friday as poor economic data from China fostered worry that it economic recovery is faltering, while travel stocks dived after the UK imposed a quarantine on people entering from France, forcing holidaymakers to rush back home to beat the weekend deadline.

In London, the blue-chip FTSE 100 index was down 131.11 points, or 2.1%, at 6,054.80 at midday. The mid-cap FTSE 250 index was off 231.02 points, or 1.3%, at 17,693.48. The AIM All-Share index was down 5.32 points, or 0.6%, at 951.48.

The Cboe UK 100 index was down 2.3% at 603.69. The Cboe 250 was down 1.4% at 15,118.68, and the Cboe Small Companies down 0.3% at 9,598.65.

Stocks in mainland Europe weren't faring much better. The CAC 40 index in Paris was down 2.1%, while the DAX 30 in Frankfurt was down 1.4%

"China was first in to the coronavirus crisis and arguably one of the first to come out of its first phase, so the fragile nature of its recovery offers an uncomfortable view of the future for other countries," said AJ Bell investment director Russ Mould.

Retail sales – a key indication of consumer sentiment – shrank by 1.1% on-year in July, falling short of forecasts and suggesting many are still reticent about going out to spend time and money, even as China appears to have the virus largely under control. The latest data follows a drop of 1.8% on-year for retail sales in June.

Meanwhile, industrial production in China grew by 4.8% in July, the same as the previous month, but below predictions of 5.2% growth.

In London, International Consolidated Airlines Group was down 5.5%. Shares in the British Airways parent were lower after the UK added France to its 14-day quarantine list.

People arriving in the UK after 0400 BST on Saturday will be required to spend 14 days in self-isolation due to rising numbers of coronavirus cases in France. The conditions also will apply to travellers returning to the UK from the Netherlands, Monaco, Malta, Turks & Caicos and Aruba.

The move, which applies throughout the UK, comes after Prime Minister Boris Johnson promised to be "absolutely ruthless" in decisions about imposing quarantine restrictions on countries.

The problem for airlines is that people's desire for a break in the sun may be outweighed by their fear of the logistical challenges of holing up for two weeks when they get back home, with decisions on which countries to add to the quarantine list often coming at short notice.

"With France being added to the quarantine list for the UK, travel & leisure is under pressure. Shares in IAG, Ryanair, Tui and EasyJet were all sharply lower as the move will force a large swathe of cancellations right at the peak of the summer holiday season for one of the largest markets for UK tourists. Half a million Brits are thought to be in France right now," noted Markets.com analyst Neil Wilson.

Irish budget carrier Ryanair Holdings was down 4.6%. UK peer easyJet was down 6.5%. Dart Group, which owns the Jet2 airline, was down 7.1%.

Anglo-German holiday operator TUI was down 5.3%.

Outside of travel stocks, Rank Group was the best mid-cap performer, up 2.4%, ahead of UK casinos being allowed to reopen on Saturday.

Casinos, bowling alleys and casinos were on the list of UK businesses that will be allowed to welcome customers back for the first time on Saturday after months of lockdown.

Hollywood Bowl Group was up 8.5%, while Ten Entertainment Group was up 3.2%.

At the other end of the FTSE 250 index, WH Smith was down 3.7%. The books and stationery retailer makes a substantial amount of its revenue from stores in airports and train stations and so also is threatened by travel restrictions.

On the AIM, Verona Pharma was up 21%. The drugmaker said the impact of Covid-19 on clinical trials in the first half has been limited.

Verona remains on track to start its Phase 3 clinical trials with ensifentrine for the treatment of chronic obstructive pulmonary disease later in 2020. It also has received a notice from US Food & Drug Administration to proceed with a study of ensifentrine in patients with Covid-19 at the University of Alabama.

In New York, the Dow Jones Industrial Average was pointed to open down 0.5%, the S&P 500 index down 0.3% and the Nasdaq Composite down 0.1%.

The pound was quoted at USD1.3094 on Friday at midday, firm from USD1.3084 at London equities close Thursday.

The euro was priced at USD1.1807, down from USD1.1830. Against the yen, the dollar was quoted at JPY106.75 in London, lower from JPY106.90.

The eurozone economy crashed 12% in the second quarter of 2020, according to figures from Eurostat on Friday.

This quarter-on-quarter decline was the worst reading since the series started in 1995. In the first three months of the year, gross domestic product fell 3.6% sequentially.

Year-on-year, the eurozone economy shrank 15% in the three months to June, again the sharpest decline seen since 1995 and a deterioration from the 3.1% fall posted for the first quarter. Two quarters in a row of contraction mean the eurozone economy has entered into recession.

In commodities, Brent oil was trading at USD44.66 a barrel Friday midday, down from USD45.18 a barrel Thursday evening in London.

Gold was quoted at USD1,950.86 an ounce at midday, slightly higher from USD1,947.60 an ounce at the London equities close Thursday.

Still to come in the economic events calendar on Friday are US retail sales figures at 1330 BST.

By Neetika Kurup; neetikakurup@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
7 Mar 2019 11:28

DIRECTOR DEALINGS: Verona Pharma Chair David Ebsworth Buys Shares

LONDON (Alliance News) - Clinical-stage biopharmaceutical company Verona Pharma PLC said on Thursday Chair David Ebsworth bought 26,300 shares for 56.30 pence each on Wednesday.Following in

Read more
4 Mar 2019 13:35

Monday broker round-up

(Sharecast News) - RSA Insurance Group: JP Morgan downgrades to neutral with a target price of 610p.

Read more
4 Mar 2019 10:12

Verona Pharma Reports Positive Data From Lung Disease Treatment Trial

LONDON (Alliance News) - Shares in Verona Pharma PLC rose on Monday following positive data from part of a Phase Two clinical trial of a dry powder inhaler formulation of Verona's ensifentrine

Read more
14 Jan 2019 10:23

WINNERS & LOSERS SUMMARY: JD Sports Rises After Strong Christmas

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - LOSERS----------Paddy Power

Read more
14 Jan 2019 09:47

Verona Pharma's Ensifentrine COPD Study Does Not Meet Primary Endpoint

LONDON (Alliance News) - Verona Pharma PLC on Monday said its phase two clinical trial of nebulized Ensifentrine did not meet its primary endpoint but did perform better than placebo.Shares

Read more
14 Jan 2019 08:48

Verona Pharma shares plunge on latest drug trial results

(Sharecast News) - Verona Pharma shares were well into the red on Monday, after the clinical-stage biopharmaceutical company announced top-line data from its latest trial of RPL554, failing to reach its primary endpoint.

Read more
9 Jan 2019 15:44

Verona Pharma granted WHO approval for Ensifentrine name

(Sharecast News) - Clinical stage biopharmaceutical outfit Verona Pharma has been granted approval of the name Ensifentrine for its first-in-class, inhaled, dual inhibitor drug candidate RPL554 by the World Health Organisation.

Read more
17 Dec 2018 14:22

Verona Pharma initiates Phase 2 study of RPL554

(Sharecast News) - Clinical-stage biopharmaceutical company Verona Pharma announced the initiation of a Phase 2 clinical trial to evaluate the pharmacokinetic (PK) profile, efficacy and safety of a dry powder inhaler (DPI) formulation of 'RPL554', in patients with moderate to severe chronic obstructive pulmonary disease (COPD), on Monday.

Read more
6 Nov 2018 11:56

Verona Pharma Third-Quarter Loss Narrows On Finance Income

LONDON (Alliance News) - Verona Pharma PLC on Tuesday said its loss narrowed by two thirds in the third quarter of 2018 on increased finance income and reduced costs as it initiated a phase two of

Read more
31 Oct 2018 12:25

Verona Pharma Completes Enrollment In Clinical Trial Of RPL554

LONDON (Alliance News) - Verona Pharma PLC said Wednesday it has completed the enrollment for its Phase 2 clinical trial evaluating the effect of nebulised RPL554 as an add-on to dual therapy in a

Read more
26 Oct 2018 11:46

Verona Pharma turns in positive data from RPL554 trials

(Sharecast News) - Clinical-stage biopharmaceutical company Verona Pharma turned in some positive data from its pre-clinical and Phase 2a trials on its potential cystic fibrosis treatment RPL554.

Read more
1 Aug 2018 12:49

Verona Pharma Starts Phase 2 Trial For Respiratory Disease Treatment

LONDON (Alliance News) - Verona Pharma PLC said Wednesday that it started the second phase of a clinical trial of its nebulized RPL554 drug for the treatment of patients with chronic obstructive 2

Read more
8 May 2018 07:01

LONDON MARKET EARLY CALL: Stocks Called Lower As Iran Fears Boost Oil

LONDON (Alliance News) - Stock prices in London are seen opening lower on Tuesday following Monday's UK bank holiday as Chinese exports recovered at a faster pace in April amid concerns the US

Read more
26 Mar 2018 10:19

Verona Pharma Shares Rise As It Gets Good Results From RPL554 Trials

LONDON (Alliance News) - Verona Pharma PLC said Monday it has received positive top-line data from its phase 2b study for its proposed RPL554 treatment.RPL554 is a for

Read more
8 Mar 2018 13:59

DIRECTOR DEALINGS: Verona Pharma CEO Karlsson Buys 3,250 Shares

LONDON (Alliance News) - Verona Pharma PLC, a clinical-stage biopharmaceutical company, said Thursday that Chief Executive Officer Jan-Anders Karlsson purchased 3,250 ordinary

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.